



Induced Pluripotent Stem Cells from Ataxia-Telangiectasia Recapitulate the Cellular Phenotype

SAM NAYLER,^{a,b} MAGTOUF GATEI,^b SERGEI KOZLOV,^b RICHARD GATTI,^c JESSICA C. MAR,^d
CHRISTINE A. WELLS,^a MARTIN LAVIN,^{b,e} ERNST WOLVETANG^a

Key Words. Experimental models • Gene expression • Reprogramming • iPS

^aAustralian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane, Queensland, Australia;

^bDepartment of Cancer and Cell Biology, Queensland Institute of Medical Research, Bancroft Centre, Brisbane, Queensland, Australia; ^cDepartment of Pathology, UCLA School of Medicine, Los Angeles, California, USA; ^dDepartment of Systems & Computational Biology, Albert Einstein College of Medicine, New York, New York, USA;

^eDivision of Cancer, University of Queensland Centre for Clinical Research, Brisbane, Queensland, Australia

Correspondence: Ernst Wolvetang, Ph.D., Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Corner of College and Cooper Road, St. Lucia, Brisbane, Queensland 4072, Australia. Telephone: 61-7-334-63894; Fax: 61-7-334-63973; e-mail: e.wolvetang@uq.edu.au; or Martin Lavin, Ph.D., Queensland Institute of Medical Research, 300 Herston Road, Herston, Brisbane, Queensland 4006, Australia. Telephone: 61-7-3362-0341; Fax: 61-7-3362-0106; e-mail: martin.lavin@qimr.edu.au

Received March 4, 2012; accepted for publication May 22, 2012; first published online in SCTM EXPRESS June 28, 2012.

©AlphaMed Press
1066-5099/2012/\$20.00/0

<http://dx.doi.org/10.5966/sctm.2012-0024>

ABSTRACT

Pluripotent stem cells can differentiate into every cell type of the human body. Reprogramming of somatic cells into induced pluripotent stem cells (iPSCs) therefore provides an opportunity to gain insight into the molecular and cellular basis of disease. Because the cellular DNA damage response poses a barrier to reprogramming, generation of iPSCs from patients with chromosomal instability syndromes has thus far proven to be difficult. Here we demonstrate that fibroblasts from patients with ataxia-telangiectasia (A-T), a disorder characterized by chromosomal instability, progressive neurodegeneration, high risk of cancer, and immunodeficiency, can be reprogrammed to bona fide iPSCs, albeit at a reduced efficiency. A-T iPSCs display defective radiation-induced signaling, radiosensitivity, and cell cycle checkpoint defects. Bioinformatic analysis of gene expression in the A-T iPSCs identifies abnormalities in DNA damage signaling pathways, as well as changes in mitochondrial and pentose phosphate pathways. A-T iPSCs can be differentiated into functional neurons and thus represent a suitable model system to investigate A-T-associated neurodegeneration. Collectively, our data show that iPSCs can be generated from a chromosomal instability syndrome and that these cells can be used to discover early developmental consequences of ATM deficiency, such as altered mitochondrial function, that may be relevant to A-T pathogenesis and amenable to therapeutic intervention. *STEM CELLS TRANSLATIONAL MEDICINE* 2012;1:523–535

INTRODUCTION

Ataxia-telangiectasia (A-T) is a rare autosomal recessive genetic disorder characterized by chromosomal instability, progressive neurodegeneration, a high risk of cancer, and immunodeficiency. *ATM*, the gene defective in A-T, was initially localized to chromosome 11q22–23 [1] and then cloned by positional cloning [2]. *ATM* is a Ser/Thr protein kinase and a member of the phosphatidylinositol 3-kinase-related protein kinase family. *ATM* is recruited to the sites of DNA double-strand breaks (DSBs) by the Mre11-Rad50-Nbs1 complex, where, in the presence of other DNA damage response proteins, it is activated and subsequently phosphorylates as many as 700 substrates involved in DNA repair and cell cycle checkpoint activation [3, 4]. Biton et al. used human embryonic stem cells (hESCs) to demonstrate that *ATM* is nuclear and that it responds to DNA DSBs [5]. More recently, *ATM* was shown to be vital for the coordination of cell cycle control of pluripotent stem cells after ionizing radiation (IR) in G₂ but not G₁ [6]. Interestingly, interference with *ATM* activity in hESCs using the specific *ATM* inhibitor KU55933 [7] or bacterial artificial chromosome (BAC)-mediated gene knockout [8] suggested that *ATM* may be dis-

pensable for repair of DSBs and genomic stability in hESCs. Although *Atm*-deficient mice recapitulate some of the cellular defects observed in A-T, including radiosensitivity, immunodeficiency, high incidence of cancer, and defective germ cell development [9, 10], other A-T-related defects, such as neuronal degeneration, are not evident in *Atm*-deficient mice, highlighting the need for a human A-T model system. Induced pluripotent stem cells (iPSCs) from individuals with A-T therefore present an opportunity to elucidate the role of *ATM* in the pluripotent context, to study A-T pathogenesis, and to create relevant patient-specific cell platforms for drug screening.

To date, the generation of iPSCs from DNA damage and chromosome instability syndromes without prior gene correction has not been reported. We found that reprogramming of A-T fibroblasts into iPSCs was indeed inefficient. Here we report on the generation and characterization of bona fide iPSCs from a family with A-T and show that these cells recapitulate important aspects of the A-T phenotype, including deregulation of molecular pathways previously associated with *ATM*, as well as gene expression changes in the pentose phosphate and mitochondrial oxidative phosphorylation pathways. These findings provide novel insights into early

developmental consequences of *ATM* deficiency that may contribute to A-T pathogenesis. We also show that A-T iPSCs are capable of generating functional neurons and thus offer a potential model system to investigate the neurodegeneration associated with this disorder.

MATERIALS AND METHODS

Generation of iPSCs

Primary fibroblasts were isolated from dermal punch biopsies collected from patients with ataxia-telangiectasia attending the A-T Clinic, University of Queensland Centre for Clinical Research. Biopsies were dissected into small pieces and incubated under coverslips in Dulbecco's modified Eagle's medium (DMEM) (Gibco, Grand Island, NY, <http://www.invitrogen.com>) with 12% fetal calf serum (FCS) until fibroblasts grew out. Primary human fibroblasts were harvested with TrypLE select (Invitrogen, Carlsbad, CA, <http://www.invitrogen.com>) and expanded in DMEM (Gibco) with 15% FCS until cryopreservation at passage 2. Fibroblasts were transduced with lentiviral constructs carrying *OCT4/IRES/SOX2* and *KLF4/IRES/c-MYC* (Adgene plasmid 21162: pSIN4-EF2-O2S and plasmid 21163: pSIN4-EF2-N2L) [11]. After transduction, >50,000 A-T fibroblasts were allowed to recover for 24–48 hours before being transferred to mouse embryonic fibroblast (MEF) feeder plates (36,000 cells per cm²). Transduced A-T fibroblasts were stepwise transferred from DMEM with 15% FCS to 100% hESC culture medium over a period of 4 days at 25% per day, as this was shown to greatly increase their survival and proliferation. In accordance with a recent attempt to standardize nomenclature across hESCs and iPSCs [12], we have named these lines UQ0001i-ATH47.x and UQ0002i-AT34.y, where UQ refers to the institution in which they originated, the subsequent four-digit number refers to the order in which they were generated, i denotes iPSC origin, and A-T or ataxia-telangiectasia heterozygote (A-Th) nomenclature was as previously developed for naming A-T-cell lines, followed by internal patient identifier and clone number (x or y). All work was carried out with informed consent from patients under the approval of the University of Queensland Human Research Ethics Committee (HREC/09/QRCH/103).

Cell Culture Conditions

hESCs and iPSCs were grown in knockout serum replacement (KOSR) hESC culture medium (80% DMEM Ham's F-12 medium [Gibco], 20% KnockOut Serum Replacement [Gibco], 2 mM L-glutamine [Gibco], 1% nonessential amino acids [Gibco], 0.1 mM 2-mercaptoethanol, and 50–100 ng/ml basic fibroblast growth factor) (Invitrogen) at 37°C at 5% CO₂ and high humidity. Cells were maintained on MEF feeder layers supplied by the Australian Stem Cell Centre. For experimentation, cells were cultured in feeder-free conditions on Matrigel (BD Biosciences, San Diego, CA, <http://www.bdbiosciences.com>) in MEF-conditioned hESC culture medium. Cells were passaged as previously described [13] before being replating at a seeding ratio of between 1:2 and 1:6. hESC medium was replaced daily, and cells were split at approximately 80% confluence on days 6–7.

Screening of Clones

iPSC colonies were picked at early (2 weeks) and late (5 weeks) time points and subcultured clonally on MEFs in organ culture dishes. Clones were screened for expression of TRA-1-60 and

Hoechst dye efflux, transgene persistence by reverse transcription-polymerase chain reaction (RT-PCR), stem cell marker expression, methylation status at *Oct4/Nanog* promoters, and karyotypic stability via G-band analysis (>15 metaphases analyzed per sample) by a commercial genotyping service (Sullivan Nicolaides Pathology, Brisbane, QLD, Australia, <http://www.snp.com.au>). Transgene silencing in selected clones was later confirmed by quantitative RT-PCR.

Teratoma Formation

iPSCs grown on MEFs were collected by collagenase IV treatment, and approximately 2×10^6 iPSCs resuspended in 50 μ l of DMEM/Ham's F-12 medium supplemented with 30% Matrigel were injected into hind limb muscles of methoxyflurane-anesthetized 6-week-old immune-compromised SCID mice (CB17-SCID mice from the Animal Resources Centre [ARC], Canning Vale, WA, Australia, <http://www.arc.wa.gov.au>). After 8–10 weeks, teratomas were dissected and fixed in 4% paraformaldehyde. Samples were embedded in paraffin, stained with hematoxylin and eosin, and examined for the presence of representatives of the three germ layers by an independent pathologist. All mouse procedures were conducted under local ethical guidelines and after gaining permission from the local animal ethics committee (University of Queensland, Brisbane, QLD, Australia).

Bisulfite Sequencing

Live iPSCs were sorted by flow cytometry for TRA-1-60, and genomic DNA was isolated. One to 2 μ g of DNA was bisulfite-converted using the EpiTect Bisulfite kit (Qiagen, Hilden, Germany, <http://www.qiagen.com>) before PCR of *Oct4/Nanog* promoter regions and cloning into the PCR2.1 vector. Clones were screened and selected for sequencing (primers are listed in supplemental online Table 8). Synthetically hypermethylated HeLa cells and H9 hESCs were also included as controls.

Irradiation

A ⁶⁰Co source irradiator was used to deliver 2 Gy of IR to the cells. Cells were returned to the incubator to recover to the appropriate time point before harvesting/fixation with 4% paraformaldehyde, lysate preparation, or processing for fluorescence-activated cell sorting (FACS).

Terminal Deoxynucleotidyl Transferase dUTP Nick-End Labeling Assay

Following IR or mock dose, cells were washed once in phosphate-buffered saline (PBS) and harvested with cell dissociation buffer (Gibco). The terminal deoxynucleotidyl transferase dUTP nick-end labeling assay was used to determine apoptosis according to the in situ cell death detection kit (Roche Diagnostics, Basel, Switzerland, <http://www.roche-applied-science.com>).

Immunoblotting

Cell extracts were prepared as previously described [14]. Proteins were separated using SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose using Towbin's buffer and 100 V for 1 hour at 4°C prior to immunoblotting. Membranes were blocked with PBS blocking buffer containing 5% skim milk and 0.05% Tween 20 for 1 hour at room temperature and incubated for 16 hours with antibodies to SMC1 (1 μ g/ml), SMC1p5957 (1 μ g/ml), KAP-1 (1 μ g/ml), or KAP-1pS824 (1 μ g/ml) (rabbit polyclonals; Novus Biologicals, Littleton, CO, <http://www.novusbiologicals.com>).

www.novusbio.com); anti-rabbit p53 (2 $\mu\text{g/ml}$) or anti-mouse p53 Ser15 (2 $\mu\text{g/ml}$) (Cell Signaling Technology, Beverly, MA, <http://www.cellsignal.com>); or anti-rabbit Chk2 (2 $\mu\text{g/ml}$), Chk2 pT68 (3 $\mu\text{g/ml}$) (Abcam, Cambridge, U.K., <http://www.abcam.com>), anti-rabbit ATM pSer1981 (2 $\mu\text{g/ml}$) (Rockland Immunochemicals, Gilbertsville, PA, <http://rockland-inc.com>), or anti-ATM (2 $\mu\text{g/ml}$) (mouse monoclonals; GeneTex, San Antonio, TX, <http://www.genetex.com>) diluted in blocking buffer at the indicated dilutions. Following washing in PBS buffer containing 0.05% Tween 20, anti-mouse horseradish peroxidase (1 $\mu\text{g}/3\text{ ml}$) (Millipore, Billerica, MA, <http://www.millipore.com>) and anti-rabbit (1 $\mu\text{g}/5\text{ ml}$) (Rockland Immunochemicals) secondary antibodies diluted in blocking buffer were used to reveal antibody binding. Secondary antibody cross-reactivity was visualized using ECL (PerkinElmer Life and Analytical Sciences, Waltham, MA, <http://www.perkinelmer.com>).

Immunostaining

For immunostaining cells were washed in PBS and fixed in 4% paraformaldehyde for 15 minutes at 4°C. For nuclear staining, samples were permeabilized in 0.1% Triton X-100 at room temperature for 10 minutes before blocking with 10% goat serum and incubation with the relevant antibodies overnight at 4°C. Antibodies and dilutions used were Oct4 (2.5 $\mu\text{g/ml}$), SSEA-4 (1/100), TRA-1-60 (2.5 $\mu\text{g/ml}$), Nanog (1/400), TRA-1-80 (3.8 $\mu\text{g/ml}$) (all from Millipore), or Oct4 (1 $\mu\text{g/ml}$) (Santa Cruz Biotechnology Inc., Santa Cruz, CA, <http://www.scbt.com>). ATM antibody preparation is described in [15]. Following washing with PBS (three times for 5 minutes at room temperature) the secondary antibodies goat anti-mouse IgG₁, goat anti-mouse IgG_{2b}, goat anti-mouse IgM, or donkey anti-rabbit IgG (Alexa Fluor) (2 $\mu\text{g/ml}$) were used to reveal cross-reactivity. Nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI) or Hoechst. This preparation minus the addition of primary antibody was used to confirm specificity of staining.

G₂/M Checkpoint Analysis

Activation of the G₂/M checkpoint was determined by histone H3 phosphorylation [16]. Immunohistochemistry for the mitosis-specific marker phosphorylated histone H3 (serine 10) (H3s10; P-Histone H3 S10; Cell Signaling Technology; 0.5 $\mu\text{g/ml}$) was performed 2 hours after 2 Gy of ionizing radiation or mock dose. The mitotic index was derived by counting the proportion of immune-positive cells for H3s10 staining divided by the number of nuclei stained by DAPI. General linear models were performed to assess for differences in the proportions for the three different groups (A-T, control iPSCs, and H9) and the irradiation states (irradiated and not irradiated). Analyses were performed on the mean arcsine square-root proportions, and the results were then back-transformed for presentation. All results presented were back-transformed to the original scale. No significant difference was found between control iPSCs and H9s, so we pooled these data to compare with A-T iPSCs. An average of >650 events were quantified from each condition in three independent experiments. Slides were imaged using an Olympus BX61 microscope (Olympus, Tokyo, <http://www.olympus-global.com>).

Radioresistant DNA Synthesis

Radioresistant DNA synthesis was determined by DNA fiber labeling as described previously [17]. Briefly, A-T and control iPSCs







were pulsed for 15 minutes with 50 μM chlorodeoxyuridine and washed, followed by exposure to mock/2 Gy of radiation prior to a second pulse for 15 minutes with 50 μM iododeoxyuridine. DNA fibers were made following the approach as previously outlined. Ongoing initiations and new replication forks were visualized via immunofluorescent microscopy after staining with rat monoclonal anti-bromodeoxyuridine (anti-BrdU) (Abcam) (13.3 $\mu\text{g/ml}$) and mouse monoclonal anti-BrdU (BD Biosciences) (1/8). Secondary antibodies were goat anti-rat Alexa 488-conjugated secondary (Invitrogen) (6.7 $\mu\text{g/ml}$) and donkey anti-mouse Alexa 594-conjugated secondary (6.7 $\mu\text{g/ml}$). Two-by-two factorial analysis of variance was performed to assess differences in the proportions of the two different genotypes (A-T vs. control) and the irradiated states (irradiated and not irradiated). Analyses were performed on the arcsine square-root proportions, and the results (means and confidence intervals) were then back-transformed for presentation. Analyses showed that there were no differences between the two substudies, and all analyses were performed on the combined data set, not taking into account the substudies. All results presented from analyses were back-transformed to the original scale. More than 700 events were quantified from each condition in two independent experiments. Slides were imaged using a Zeiss LSM 710 confocal microscope (Carl Zeiss, Jena, Germany, <http://www.zeiss.com>).

Neuronal Differentiation

iPSC cultures were grown for 5 days after passage prior to commencement of differentiation and changed directly into KOSR hESC medium supplemented with 5 μM dorsomorphin (Stemgent, Cambridge, MA, <https://www.stemgent.com>) and 10 μM SB431542 for the first 6 and 12 days of differentiation, respectively, with medium changes every 2 days. The KOSR hESC medium was gradually replaced with Neurobasal medium (Gibco) (with N2B27 supplements used according to the manufacturer's specifications) (Gibco) with 25%, 50%, 75%, and 100% N2B27 Neurobasal medium in KOSR hESC medium on days 4, 6, 8, and 10 respectively. Neurospheres were formed on day 6 of differentiation by 10 minutes of incubation in 1 mg/ml collagenase IV (Gibco) at 37°C and dislodging of large pieces of colonies by use of a cell scraper and P1000 pipette. Neuralized colony fragments were seeded into Ultra-Low Cluster plates (Corning Costar, Acton, MA, <http://www.corning.com/lifesciences>), where they aggregated into tight spheres. On day 12 of differentiation, neurospheres were seeded onto Matrigel (BD Biosciences)-coated plates, and N2B27 Neurobasal medium was subsequently changed every 3–4 days as neurons grew out from the sphere borders. Cultures were passaged every week by cell dissociation buffer (Sigma-Aldrich, St. Louis, <http://www.sigmaaldrich.com>) at a ratio of 1:2 to 1:3, eventually leading to the complete dissociation of neurosphere aggregates. Four- to 6-week-old cultures were subsequently matured by the addition of 20 ng/ml brain-derived neurotrophic factor and 20 ng/ml glial cell line-derived neurotrophic factor (R&D Systems Inc., Minneapolis, <http://www.rndsystems.com>), 200 nM ascorbic acid, and 0.5 mM dibutyryl-cAMP (Sigma-Aldrich) for 2 weeks with medium changes every 2 days to replenish growth factors.

Calcium Imaging in Neuronal Cultures

Calcium imaging was performed using the FLIPR TETRA High Throughput Cellular Screening System (Molecular Devices, Sunnyvale, CA, <http://www.moleculardevices.com>), essentially



as described by Vetter and Lewis [18]. Neurons were seeded in a black-walled 386-well culture format, loaded with a calcium-sensitive fluorescent dye, and depolarized with 50 mM KCl.

RNA Isolation, cDNA Synthesis, PCR, and Quantitative PCR

RNA was isolated using the RNeasy isolation kit (Qiagen). Concentration and 260/280 ratios were quantified using a NanoDrop 1000 spectrophotometer (NanoDrop, Wilmington, DE, <http://www.nanodrop.com>) before synthesis of cDNA using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, <http://www.bio-rad.com>) according to the manufacturer's specifications (500 ng). RT-PCR was performed for *OCT4* (657 base pairs [bp]) and *SOX2* (498 bp) transgenes according to the following conditions: 94°C for 5 minutes; 32 cycles of 94°C for 1 minute, 58°C for 30 seconds, and 72°C for 1 minute; 72°C for 7 minutes. RT-PCR was performed for *KLF4* (563 bp) and *c-MYC* (350 bp) transgenes and for *GAPDH* (152 bp) according to the following conditions: 94°C for 5 minutes; 32 cycles of 94°C for 1 minute, 57°C for 30 seconds, and 72°C for 1 minute; and 72°C for 7 minutes. Primers are listed in supplemental online Table 8. Quantitative PCR (qPCR) was performed for the *OCT4* transgene, endogenous *OCT4*, and β -*Actin* using a C1000 thermal cycler (Bio-Rad) using Ssofast evagreen qPCR mix (Bio-Rad) according to the following conditions: 95°C for 3 minutes; 30 cycles of 95°C for 10 seconds and 60°C for 30 seconds. Expression data were calculated using the $\Delta\Delta Ct$ method.

Expression Analysis

RNA was harvested from TRA-1-60 FACS-sorted hESCs (MEL1) and control (UQ0001i-control1), A-T heterozygote (UQ0001i-ATH47.1), and homozygote iPSCs (UQ0002i-AT34.7), as well as from nonsorted parental fibroblasts. Total RNA was isolated from each FACS-sorted iPSC line and from unsorted fibroblast cell samples using the RNeasy Mini Kit (Qiagen). The total RNA (and A260/A280 ratio) was then quantified using a NanoDrop 1000 spectrophotometer. Total RNA (100 ng) was subjected to reverse transcription, second-strand cDNA synthesis, and in vitro transcription using the TotalPrep RNA Amplification Kit (Illumina Inc., San Diego, <http://www.illumina.com>). cRNA was hybridized to Illumina HT12 v4 BeadChip microarrays. The raw expression data were normalized using quantile normalization and without background correction, using the lumi R/Bioconductor package (version 2.4.0) [19]. Only probes passing the Illumina detection threshold were included in the expression analysis; a probe passed the Illumina detection score if it had a detection p value of

$\leq .01$ in at least 75% of cell lines in the same group; these criteria resulted in 20,593 probes being retained. All statistical analyses were performed using R, version 2.13.2. All probes were mapped using the annotation package *illuminaHumanv4.db* (version 1.10.0) available from Bioconductor. The expression data are available for download from Stemformatics (<http://www.stemformatics.org>) and GEO (<http://www.ncbi.nlm.nih.gov/geo>) under the accession number GSE35347.

Heatmaps were constructed using the *gplots* R/Bioconductor package (version 2.10.1) where agglomerative hierarchical clustering was used on the basis of a measure of dissimilarity $1 - R$, where R represents the Pearson correlation coefficient between any two gene expression profiles and ranges from -1 to 1 . Probes mapping to multiple gene symbols were filtered to ensure a one-to-one mapping between probe and gene symbol; the probe with the most significant p value assessing the significance of differential expression between A-T and control iPSCs was retained and represented in the resulting heatmap. The p values were generated using the R/Bioconductor package *limma* (version 3.8.3) and adjusted for multiple testing using the Benjamini-Hochberg method [20]. The PluriNet gene list, as identified by Müller et al., was originally downloaded from <http://www.stemcellmatrix.org> and consisted of 299 gene symbols, listed in supplemental online Table 9 [21]. Pathway analysis was performed using the R/Bioconductor package *attract* (version 1.4.0) [22], where pathways were defined using the *Kyoto Encyclopedia of Genes and Genomes* (KEGG) [23]. The comparison of expression between mitochondrial genes in A-T and control iPSCs was based on genes represented in MitoCarta, a curated list of genes known to be involved in mammalian mitochondrial function. We used *attract* to compute a p value representing the enrichment of genes showing differential expression across the seven cell types for which expression analysis was present. We found that the mitochondrial gene list had a statistically significant p value of 9.47×10^{-19} , and we were able to decompose this pathway into four groups of genes showing distinct patterns of correlated expression.

RESULTS

Generation and Characterization of A-T Homozygote and A-T Heterozygote iPSCs

Skin fibroblast cultures were established from punch biopsies from A-T heterozygote and A-T homozygote patients (mother

Figure 1. Generation of A-T heterozygote and homozygote induced pluripotent stem cells (iPSCs). **(A):** The mean number of colonies following reprogramming of control ($n = 3$), A-T heterozygote ($n = 3$), and A-T homozygote ($n = 2$) fibroblasts. The figure shows pooled data from more than one experiment. **(B):** Polymerase chain reaction (PCR) analysis of transgene expression and endogenous expression of *NANOG* and *OCT4* in homozygote and heterozygote A-T iPSCs. Arrows indicate the two clones (C7 and C11) with the greatest levels of transgene silencing. Positive controls were lentiviral plasmids and H9 hESC cDNA. **(C):** Quantitative PCR data show that the transgene was detectable in transduced fibroblasts at 168 and 208 hours post-transduction, but not in control fibroblasts. Transgene *OCT4* was not detected in A-T iPS (C7) but was present in trace amount in A-Th iPS (C1) after 30 weeks of passage. Results were normalized to a control iPS clone that expressed transgene robustly. Both A-T iPS (C7) and A-Th iPS (C1) strongly expressed endogenous *OCT4*. Error bars show SEM from three technical replicates; data are from one experiment. Primers for β -*ACTIN* were used as a control. **(D):** A-T iPS (C7) colonies expressed the following pluripotency markers: *OCT4*, *NANOG*, *Tra-1-80*, *Tra-1-61*, *SSEA4*. DAPI stained the nuclei. Scale bars = $1 \mu\text{m}$. **(E):** Bisulfite sequencing of CpG islands in the *NANOG* and *OCT4* promoters in nuclear DNA from heterozygote A-T fibroblasts (A-Th-F) and heterozygote A-T iPSCs (A-Th-iPS C1) and homozygote A-T fibroblasts (A-T-F) and A-T iPSCs (A-T-iPS C7). Methylated HeLa DNA (positive control) and H9 hESC DNA (negative control) are also shown. Open circles represent unmethylated dinucleotides, and closed circles represent methylated dinucleotides. **(F):** Hierarchical clustering and heatmap comparison of the 299 PluriNet genes between control fibroblasts, homozygote A-T fibroblasts, heterozygote A-T fibroblasts, heterozygote A-T iPSCs (C1), homozygote A-T iPSCs (C7), H9 hESCs, and control iPSCs. Abbreviations: A-T, ataxia-telangiectasia; A-Th, ataxia-telangiectasia heterozygote; C, clone; CTRL, control; DAPI, 4',6-diamidino-2-phenylindole; F, fibroblast; hESC, human embryonic stem cell; iPS, induced pluripotent stem; Pos, positive; TG, transgene.

and daughter). Mutation analysis revealed two frameshift deletions (7004delCA and 7886delTATTA) predicted to result in truncated and thus unstable ATM protein [24]. In order to optimize conditions and reduce the risk of chromosomal instability, we selected early passage (passage <5) fibroblasts for reprogramming. Following transduction with *OCT4*/IRES/*SOX2* and *KLF4*/IRES/*c-MYC* lentivirus, we stepwise adapted the cells to KOSR hESC culture medium over the first 4–5 days of iPSC generation, since direct replacement with KOSR hESC culture medium was found to lead to extensive death of the A-T fibroblasts. Control cells from healthy, unrelated individuals were also reprogrammed in parallel. After 2 weeks, transduced A-T patient fibroblasts gave rise to hESC-like colonies (supplemental online Fig. 1A). Although our data show that it was possible to reprogram A-T fibroblasts, the efficiency was markedly reduced to 4% compared with controls (Fig. 1A). It is also of note that reprogramming efficiency was reduced to 15% for the A-T heterozygote, indicating a potential role for ATM in reprogramming. Thirteen colonies from the ATM homozygote patient that expressed the TRA-1-60 stem cell surface marker and exhibited Hoechst dye efflux [25] (supplemental online Fig. 1B) were expanded for further analysis. Eleven of these clones displayed a stable pluripotent stem cell phenotype and could be culture expanded. Two of the A-T homozygote clones (C7 and C11) and one clone (C1) of the heterozygote samples were selected for further analysis as these showed *SOX2*, *KLF4*, and *c-MYC* transgene silencing after 13 weeks of culture with some persistence of *OCT4* transgene (Fig. 1B). A-T iPSC clones 7 and 11 robustly expressed endogenous *OCT4* and *NANOG*, as shown by RT-PCR (*OCT4*) (Fig. 1B). Following 30 weeks of culture, quantification of *OCT4* transgene expression by qPCR in A-T iPSC clone 7 and A-Th iPSC clone 1 revealed that exogenous *OCT4* expression was undetectable (C7) or present in trace amounts (C1), relative to controls (Fig. 1C). These clones further exhibited clearly detectable expression of the pluripotency markers TRA-1-60, TRA-1-81, SSEA4, *NANOG*, and *OCT4* by immunofluorescence (Fig. 1D; supplemental online Fig. 1C). Immunoblotting failed to detect ATM protein in protein extracts from the patient fibroblasts (Fig. 2A). Flow cytometric analysis of TRA-1-60 expression further exemplifies that the A-T iPSCs (clone 7 shown) exhibit robust and uniform expression of this pluripotency marker in the majority of the population (supplemental online Fig. 1D). In keeping with these observations, CpG islands in the *OCT4* and *NANOG* promoter regions in the A-T iPSCs (clone 7) and A-Th-iPSCs (clone 1) were found to be hypomethylated as compared with the parental fibroblasts (Fig. 1E). Heterozygote and control clones were screened similarly as described above and conformed to the same criteria (data shown where applicable).

iPSCs from both the A-T homozygote (clones 7 and 11) and their A-T heterozygote parent (clone 1) formed teratomas when injected into SCID mice (one mouse per line, with each mouse developing a teratoma) comprising tissue types from all three germ layers (endoderm, mesoderm and ectoderm), indicating pluripotential trilineage differentiation (supplemental online Fig. 1E), as did control iPSCs (supplemental online Fig. 1E). A subset of the 11 clones that displayed the characteristics of pluripotent cells were examined for gross karyotypic abnormalities (supplemental online Fig. 2). Although 2 of the 11 clones that displayed long-term self-renewal developed chromosomal abnormalities, 5 A-T iPSC clones displayed normal karyotypes between passage 11 and passage 16, and this was maintained out to passage 31 in

the case of one A-T clone (clone 7) (supplemental online Table 1). To further validate the A-T iPSCs, we compared the transcriptome of A-T iPSC clone 7 with control iPSCs (UQ0001i-control1) and hESCs (MEL1). Principal component analysis revealed the similarity in gene expression between A-T iPSCs, control iPSCs, and hESCs, and this was further reinforced by hierarchical clustering of the 299 pluripotency-associated genes of the PluriNet [21] (Fig. 1F). We conclude from these analyses that the phenotype and gene expression profiles of A-T homozygote (and UQ0002i-AT34.7) and heterozygote (UQ0001i-ATH47.1) iPSC lines are consistent with a fully reprogrammed iPSC phenotype.

Defective DNA Damage Response in A-T iPSCs

ATM is a cellular DNA damage sensor that coordinates the cell cycle through damage-response checkpoints and mediates DNA repair to preserve genomic integrity. ATM has also been implicated in additional roles such as regulation of metabolic activity and response to reactive oxygen species (ROS) [24, 26]. There is still little consensus regarding the role of *ATM* in human pluripotent stem cells, and we therefore investigated several A-T-associated phenotypes in the A-T iPSCs.

The A-T patient in this study possesses frameshift mutations in both *ATM* alleles; accordingly neither the A-T fibroblasts (Fig. 2A) nor the A-T iPSCs (Fig. 2A) showed expression of ATM protein. This was confirmed by immunofluorescent imaging, revealing predominantly nuclear localization of ATM in control iPSCs and undetectable ATM in A-T iPSCs (Fig. 2B). Consequently, after exposure to radiation (2 Gy, 1 hour) and immunoprecipitation with ATM, phosphospecific antibodies that detect S367, S1981, or S2996 phosphorylation sites, ATM autophosphorylation was not detected, whereas autophosphorylation was clearly detected in control iPSCs (Fig. 2C). In agreement with these data, immunofluorescent staining failed to detect ionizing radiation-induced foci in irradiated A-T iPSCs (ATM pS1981 or ATM pS367), whereas clear nuclear localization of ATM pS367 and ATM pS1981 was detected in irradiated control iPSCs (Fig. 2D). γ H2AX foci were present in both controls and A-T iPSCs, indicating that DNA repair was actively proceeding in the absence of ATM protein (Fig. 2D). Once ATM is activated it phosphorylates a large number of substrates in multiple pathways [3, 14, 27], including proteins involved in cell cycle control (e.g., p53 and Chk2), cell survival (SMC1), and maintaining chromatin structure (Kap1). In control iPSCs, all of these substrates were phosphorylated and p53 was stabilized in response to radiation exposure, but this did not occur in A-T iPSCs (Fig. 2E). We conclude that ionizing radiation-induced ATM-dependent signaling is defective in A-T iPSCs.

Defective Cell Cycle Checkpoint Activation in A-T iPSCs

Another cellular hallmark of A-T is defective cell cycle checkpoint activation in response to DNA DSBs [28]. We therefore measured G₂/M delay using histone H3 phosphorylation after exposure to 2 Gy of radiation. Control iPSCs showed characteristic inhibition of entry into mitosis 2 hours after exposure to 2 Gy, similar to H9 hESCs (Fig. 3A), whereas A-T iPSCs exhibited a greatly reduced inhibition of mitotic entry after the same dose of radiation. Exposure of cells to radiation leads to rapid inhibition of DNA synthesis, and this is used to determine the intra-S-phase checkpoint [17]. When somatic A-T-cells are irradiated they exhibit radioresistant DNA synthesis or a defective S-phase checkpoint [29]. The S-phase checkpoint was determined using a DNA fiber




Figure 3. A-T induced pluripotent stem cells (iPSCs) exhibited cell cycle defects and hypersensitivity after ionizing radiation. **(A):** H3s10 immunostaining of cells following 2 Gy of ionizing radiation (IR) or mock dose was quantified. A-T iPSCs showed persistent staining relative to controls (top panels, H9 human embryonic stem cells and control iPSCs shown), indicative of a failure to arrest at the G₂/M checkpoint (>600 events were quantified from each condition in three independent experiments; error bars show SEM; $p < .05$). Scale bars = 25 μm . **(B):** A-T iPSCs exhibited radioresistant DNA synthesis following 2 Gy of IR (>700 events were quantified from each condition in two independent experiments; error bars show SEM; $p < .05$). Scale bars = 16 μm . **(C):** Flow cytometric quantification of TUNEL staining of control and A-T iPSCs 24 hours after mock or 2 Gy of IR. Populations were gated to exclude cellular debris and autofluorescence. Positive control was DNase-treated iPSCs (histograms shown in supplemental online Fig. 3) ($n = 1$). Abbreviations: A-T, ataxia-telangiectasia; iPS, induced pluripotent stem; TUNEL, terminal deoxynucleotidyl transferase dUTP nick-end labeling.

controls. In somatic cells, ATM activation by DNA DSBs and subsequent signaling through p53 represents a major pathway for induction of apoptosis [32], implying that loss of ATM activity may confer resistance to apoptosis. In contrast our data show an increased sensitivity to spontaneous and radiation-induced apoptosis.

Bioinformatic Analysis of Transcriptome Changes in A-T iPSCs

In addition to its role in responding to DNA DSB repair, ATM has also been implicated in a range of other cellular processes, and its role in nonirradiated pluripotent cells has remained largely unexplored. We therefore examined in detail the transcriptome of unchallenged A-T iPSCs in culture using a combinatorial bioinformatics approach using the *GeneGo* and *attract* bioinformatic analysis tools. Whereas *GeneGo* identifies pathways within significantly differentially expressed genes on the basis of existing knowledge (on the basis of KEGG annotation) the *attract* path-

way analysis tool examines the entire data set and identifies and amplifies new coordinately regulated gene sets that are relevant to the mechanisms underlying particular phenotypes [22].

Principal component analysis of the entire data set (Fig. 4A) showed that A-T homozygote, A-T heterozygote, wild-type iPSCs, and hESCs clustered together closely but away from the fibroblast samples, which did show clustering based on genotype. These data indicate that the large transcriptome differences that exist between A-T fibroblasts and wild-type fibroblasts are largely resolved after reprogramming. Nevertheless 7,921 genes showed differential expression between A-T and wild-type iPSCs ($p < .05$) (supplemental online Table 2). *GeneGo* analysis of this cohort of genes identified pathways previously associated with ATM, such as cell cycle control, DNA damage, and apoptosis (supplemental online Table 3). When we used *attract* to analyze the entire data set, we identified not only these known pathways but also oxidative phosphorylation and pentose phosphate pathway as significantly altered (supplemental online Fig. 4). This led us to




Figure 4. Bioinformatic analysis of A-T induced pluripotent stem cells (iPSCs) revealed mitochondrial gene expression changes. **(A)**: Principal component analysis of the entire gene expression data sets of A-T heterozygote fibroblasts and iPSCs, A-T homozygote fibroblasts and iPSCs, control fibroblasts and iPSCs, and MEL1 hESCs. **(B)**: Heatmap comparison of 546 mitochondria-associated genes (MitoCarta) between A-T heterozygote fibroblasts and iPSCs, A-T homozygote fibroblasts and iPSCs, control fibroblasts and iPSCs, and MEL1 hESCs. **(C)**: On the basis of a gene list of mitochondria-associated genes, the (MitoCarta) *attract* analysis identified four groups of mitochondria-associated gene expression showing distinct patterns of correlated expression depending on cell type or genotype. **(D)**: Expression of 141 genes expressed in mitochondria derived from group 4 (iPSC-specific changes in A-T iPSCs from [B]). Graph indicates log fold change of group 4 genes compared with control iPSCs and MEL1 hESCs. Abbreviations: A-T, ataxia-telangiectasia; ATMhet, heterozygote; ATMhomo, homozygote; hES, human embryonic stem; hESC, human embryonic stem cell; iPS, induced pluripotent stem; WT, wild-type.

analyze the expression of 1,080 genes, previously identified in the MitoCarta database [33], that are directly or indirectly associated with mitochondrial function within the 7,921 genes that were differentially expressed ($p < .05$) between A-T iPSCs and controls. Remarkably, 464 of 1,080 of these mitochondria-associated genes were identified within the A-T iPSCs differentially expressed gene list (heatmap shown in Fig. 4B), suggesting that mitochondrial function is a significantly altered pathway in non-irradiated A-T iPSCs (supplemental online Table 5 shows list of upregulated and downregulated genes). Using *attract* we were further able to attribute these mitochondrial gene expression differences to either cell state (i.e., induced pluripotent stem + embryonic stem vs. fibroblasts) or genotype (i.e., A-T homozygous + heterozygous vs. wild-type), identifying four groups (supplemental online Fig. 5 shows statistical analyses) of mitochondrial activity. In two of these groups (groups 2 and 3) *ATM* deficiency showed no difference, whereas group 1 consisted of conserved *ATM*-centric changes that were apparent in both fibroblasts and pluripotent cells (Fig. 4C). Most interestingly,

group 4 identified 212 mitochondria-associated genes that were specifically altered in A-T iPSCs but not in fibroblasts (supplemental online Table 6 shows gene lists of all four groups). Further curation of this list selecting for genes either encoded by mtDNA or imported into mitochondria shows that 140 of 143 truly mitochondrial genes were upregulated in A-T iPSCs (Fig. 4D). The majority of these 143 genes are either components of the respiratory chain, involved in assembly and import of respiratory chain complexes, mitochondrial metabolite transporters, mitochondrial ribosomal proteins, or tRNA synthetases (supplemental online Table 7 shows an annotated gene list). These gene expression changes are therefore consistent with an upregulation of mitochondrial biogenesis in human pluripotent cells in the absence of *ATM*.

Directed Differentiation of A-T iPSCs into Functional Neurons

We next differentiated A-T iPSCs (UQ0002i-AT34.7) and control iPSCs (UQ0001i-control1) into neuronal progenitors using a




Figure 5. Directed differentiation of A-T induced pluripotent stem cells (iPSCs) into mature neurons. **(A):** Schematic representation of neural induction protocol involving stepwise addition of N2B27 neurobasal medium and small molecules SB431542 and dorsomorphin for the first 6 and 12 days, respectively. Neurospheres were generated on day 6 of induction and plated after day 12, giving rise to colonies with neuronal projections and morphologies that were β III-TUBULIN- and MAP-2-positive. **(B):** Depolarization-induced calcium transients in control and A-T iPSC-derived neuronal cultures following in vitro maturation. A representative experiment is shown. **(C):** Immunofluorescent detection of β III-TUBULIN and radiation-induced (2 Gy, 1 hour) foci (ATM pS1981 and SMC1 pS957) in control iPSCs and A-T iPSCs. 4',6-Diamidino-2-phenylindole stained the nuclei. Scale bars = 10 μ m (left panel), 1 μ m (right panels). Abbreviations: A-T, ataxia-telangiectasia; B-TUBIII, β III-TUBULIN; D, day; iPSC, induced pluripotent stem.

modified version of the dual SMAD inhibition protocol previously described [34] (Fig. 5A). A-T iPSCs readily differentiated into β III-TUBULIN and MAP-2-expressing cells with a neuronal morphology that, after 2 weeks of culture in neuronal maturation medium, displayed electrophysiological activity in the form of calcium spikes following KCl depolarization, as shown by Ca^{2+} imaging performed using the FLIPR TETRA High Throughput Cellular Screening System [18] (Fig. 5B). When irradiated, these cells also exhibited a defective DNA damage response, as shown by the absence of ionizing radiation-induced foci, relative to controls (ATM S1981 and SMC1 S957) (Fig. 5C).

DISCUSSION

Emerging evidence suggests that the DNA damage pathways are activated early during reprogramming and may pose a barrier to iPSC generation. The generation of iPSCs from chromosomal instability syndromes has indeed proven to be difficult without gene manipulation. Raya et al. showed that somatic cells from patients with the rare recessive chromosomal instability disorder Fanconi anemia could be reprogrammed to pluripotency to generate patient-specific iPSCs only after correction of the defective gene with cDNA [35]. We have shown that this is not necessary, by demonstrating for the first time that fibroblasts from patients with A-T, a syndrome characterized by genome instability, can be reprogrammed to pluripotency and meet all the established criteria for bona fide iPSCs. The efficiency of reprogramming A-T fibroblasts to iPSCs was ap-

proximately 4% of that seen with controls, with heterozygotes of intermediate efficiency. This is in keeping with the observation that reprogramming of mouse *Atm*-deficient tail-tip fibroblasts occurs with efficiency less than 2% of that of wild-type fibroblasts [36]. During the process of reprogramming, cells may be less tolerant of the presence of DNA damage where p53 may play an important role in removing these cells by inducing apoptosis [37]. It is likely that the accumulation of DNA DSBs during reprogramming of A-T fibroblasts renders these cells more susceptible to apoptosis or makes them otherwise unavailable for reprogramming. Short telomeres also contribute to the barrier of cell reprogramming imposed by p53 [38]. This is also significant for A-T since fibroblasts and lymphoblastoid cells from these patients are characterized by abnormally short telomeres [39, 40]. We show that these iPSCs recapitulate key features of the A-T cellular phenotype, including radiation-induced cell cycle defects (radioresistant DNA synthesis/reduced delay at G_2/M), which is supported by numerous transcriptional changes in DNA damage and cell cycle-related processes. A-T iPSCs also show an increased sensitivity to spontaneous and radiation-induced apoptosis. A similarly increased cell death phenotype was previously reported by Ivanov et al. [41] in human melanoma cells treated with *ATM* small interfering RNA (siRNA).

iPSCs from *Atm*-deficient mice were previously found to accumulate abnormal genome structures with continuing passage [36], whereas hESCs genetically modified with a BAC-based homologous recombination system to knock out *ATM* were devoid of gross genomic abnormalities after extended culture [8]. In our

study we were also able to culture karyotypically normal human A-T iPSCs for more than 20 weekly passages. Our data are thus in agreement with recent reports showing that ATM-independent homologous repair and recombination is the principal mediator of DNA damage in pluripotent stem cells [42]. This notion is further supported by a 10-fold elevation of Rad51 foci in embryonic stem cells (ESCs) compared with differentiated astrocytes [7] and by the fact that ATM signaling proceeds in a heterochromatin-dependent manner, whereas ESCs are largely euchromatic [43].

Our pathway and phenotypic analysis of A-T iPSCs supports the prediction that ATM plays a role in the DNA damage response and cell cycle control in pluripotent cells and confirms the observations made by Momcilovic et al., who used the ATM inhibitor KU55933 to show that ATM function is essential for induction of G₂ arrest in irradiated hESCs [44]. The A-T iPSCs further behave similarly to hESCs in which ATM has been abrogated by disruption of the gene [8] or by siRNA knockdown [5].

It is becoming increasingly clear that in addition to its nuclear role in DSB repair, cytosolic ATM also functions as an ROS sensor [24, 26] and can be associated with mitochondria [45]. The *attract* pathway analysis of A-T iPSCs and fibroblasts uncovered extensive differences in the regulation of oxidative phosphorylation genes, supporting a defect at the level of the mitochondrion specifically in pluripotent A-T-cells. Previous reports suggested that loss of ATM function in somatic cells caused reduced mitochondrial function and/or abnormal homeostasis [46–48]. It was recently demonstrated that ATM-mediated mitochondrial defects are highly cell context-dependent and that in thymocytes from *Atm*-deficient mice there is in fact an increase in mitochondrial number and mitochondrial ROS production due to a defect in mitophagy [45]. In strong agreement with these data, our gene expression analysis shows that in addition to a dramatic increase in mitochondrion-associated transcripts, mRNA expression of *HMGB1* and *HSPB1* [49, 50], two important regulators of mitophagy, is specifically reduced in A-T iPSCs but not in A-T fibroblasts, suggesting that mitophagy may be specifically impaired in *ATM*-deficient iPSCs. A failure to clear mitochondria with low membrane potential, reduced ATP production, elevated ROS production, and consequently increased mtDNA mutations is consistent with the increased oxidative stress reported in A-T-cells [46, 51, 52], the increased mtDNA mutations reported in tissues of A-T patients [47], and the observation that cerebellar Purkinje cell death and neurological deficits in *Atm*-deficient mice can be rescued by antioxidants [53–55]. It is not unlikely that in response to the increased oxidative stress in A-T-cells, possibly arising from mitochondrial dysfunction, carbohydrate metabolism is rerouted from glycolysis to the pentose phosphate pathway. Our gene expression data indeed identified the pentose phosphate pathway as a significantly altered and revealed that G6PD is down-regulated in A-T iPSCs, in agreement with a recent report showing that ATM activates the pentose phosphate pathway by stimulating complex formation between heat shock protein 27 and G6PD to increase G6PD activity [56]. Of additional interest, we observed significant upregulation of *USMG5*, a gene recently implicated in human inherited ataxia and Purkinje cell degeneration [57]. If one accepts that iPSCs are equivalent to hESCs derived from the inner cell mass, it appears reasonable to hypothesize that increased mitochondrial biogenesis accompanied by defective mitophagy may lead to an accumulation of defective high ROS producing stem and

progenitor cells and that this DNA damage response-independent function of *ATM* could contribute to the pathology of A-T.

Our data demonstrating that *ATM* deficiency does not disrupt gross neuronal differentiation suggests that iPSCs may be able to be used for screening of drugs aimed at promoting survival of cell types affected in A-T, such as Purkinje cells in at the cerebellum. Generation of mature cerebellar Purkinje cells from mouse embryonic stem cells was only recently described [58, 59] and provides proof of concept that selective preparation of Purkinje neurons or committed Purkinje neuron precursors from A-T iPSCs may be possible.

CONCLUSION

In summary, we have demonstrated for the first time the generation of iPSCs from a patient with a chromosomal breakage disorder, in this case A-T, without the requirement for correcting the genetic defect in advance. We have shown that A-T iPSCs are pluripotent and provide further evidence implicating roles for ATM in DNA damage-dependent signaling in pluripotent cells. In addition to this, we have shown that it is possible to maintain a number of clones, one to high passage, that were stable in culture. Extensive transcriptional profiling and analysis of mutant and wild-type human iPSCs and parental fibroblasts showed gene expression changes in human pluripotent stem cells and allowed the identification of DNA damage, cell cycle regulation, pentose phosphate metabolism, and mitochondrial oxidative phosphorylation defects as early ATM-mediated phenotypes. It was possible to generate functionally active neurons using published protocols, providing a tool that may be used to further the understanding of this disease.

ACKNOWLEDGMENTS

We gratefully acknowledge the Stemcore facility for cell culture support. We also thank Louise Marquart (Queensland Institute of Medical Research) and Katia Nones (Queensland Centre for Medical Genomics) for expert technical support and the BrAshA-T Foundation and the Australian National Health and Medical Research Council for financial support. We thank Aine Farrell and Jian Sun for their assistance with tissue culture.

AUTHOR CONTRIBUTIONS

S.N.: conception and design, collection and assembly of data, data analysis and interpretation, manuscript writing; M.G., S.K., and R.G.: collection and assembly of data; J.C.M.: data analysis and interpretation, manuscript writing; C.A.W.: data analysis and interpretation, final approval of manuscript; M.L.: conception and design, financial support, provision of study material/patients, data analysis and interpretation, manuscript writing, final approval of manuscript; E.W.: conception and design, financial support, provision of study material/patients, collection and assembly of data, data analysis and interpretation, manuscript writing, final approval of manuscript.

DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

The authors indicate no potential conflicts of interest.

REFERENCES

- 1 Gatti RA, Berkel I, Boder E et al. Localization of an ataxia-telangiectasia gene to chromosome 11q22–23. *Nature* 1988;336:577–580.
- 2 Savitsky K, Sfez S, Tagle DA et al. The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species. *Hum Mol Genet* 1995;4:2025–2032.
- 3 Bensimon A, Schmidt A, Ziv Y et al. ATM-dependent and -independent dynamics of the nuclear phosphoproteome after DNA damage. *Sci Signal*. 2010;3:rs3.
- 4 Matsuoka S, Ballif BA, Smogorzewska A et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. *Science* 2007;316:1160–1166.
- 5 Biton S, Gropp M, Itsykson P et al. ATM-mediated response to DNA double strand breaks in human neurons derived from stem cells. *DNA Repair (Amst)* 2007;6:128–134.
- 6 Momcilovic O, Choi S, Varum S et al. Ionizing radiation induces ataxia telangiectasia mutated-dependent checkpoint signaling and G(2) but not G(1) cell cycle arrest in pluripotent human embryonic stem cells. *STEM CELLS* 2009;27:1822–1835.
- 7 Adams BR, Golding SE, Rao RR et al. Dynamic dependence on ATR and ATM for double-strand break repair in human embryonic stem cells and neural descendants. *PLoS One* 2010;5:e10001.
- 8 Song H, Chung SK, Xu Y. Modeling disease in human ESCs using an efficient BAC-based homologous recombination system. *Cell Stem Cell* 2010;6:80–89.
- 9 Elson A, Wang Y, Daugherty CJ et al. Pleiotropic defects in ataxia-telangiectasia protein-deficient mice. *Proc Natl Acad Sci USA* 1996;93:13084–13089.
- 10 Lavin MF. Ataxia-telangiectasia: From a rare disorder to a paradigm for cell signalling and cancer. *Nat Rev Mol Cell Biol* 2008;9:759–769.
- 11 Yu J, Hu K, Smuga-Otto K et al. Human induced pluripotent stem cells free of vector and transgene sequences. *Science* 2009;324:797–801.
- 12 Luong MX, Auerbach J, Crook JM et al. A call for standardized naming and reporting of human ESC and iPSC lines. *Cell Stem Cell* 2011;8:357–359.
- 13 Thomson JA, Itskovitz-Eldor J, Shapiro SS et al. Embryonic stem cell lines derived from human blastocysts. *Science* 1998;282:1145–1147.
- 14 Gatei M, Jakob B, Chen P et al. ATM protein-dependent phosphorylation of Rad50 protein regulates DNA repair and cell cycle control. *J Biol Chem* 2011;286:31542–31556.
- 15 Kozlov S, Gueven N, Keating K et al. ATP activates ataxia-telangiectasia mutated (ATM) in vitro. Importance of autophosphorylation. *J Biol Chem* 2003;278:9309–9317.
- 16 Hans F, Dimitrov S. Histone H3 phosphorylation and cell division. *Oncogene* 2001;20:3021–3027.
- 17 Parra I, Windle B. High resolution visual mapping of stretched DNA by fluorescent hybridization. *Nat Genet* 1993;5:17–21.
- 18 Vetter I, Lewis RJ. Characterization of endogenous calcium responses in neuronal cell lines. *Biochem Pharmacol* 2010;79:908–920.
- 19 Du P, Kibbe WA, Lin SM. lumi: A pipeline for processing Illumina microarray. *Bioinformatics* 2008;24:1547–1548.
- 20 Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. *J R Stat Soc Ser B Method* 1995;57:289–300.
- 21 Müller FJ, Laurent LC, Kostka D et al. Regulatory networks define phenotypic classes of human stem cell lines. *Nature* 2008;455:401–405.
- 22 Mar JC, Matigian NA, Quackenbush J et al. *attract*: A method for identifying core pathways that define cellular phenotypes. *PLoS One* 2011;6:e25445.
- 23 Kanehisa M, Goto S, Kawashima S et al. The KEGG resource for deciphering the genome. *Nucleic Acids Res* 2004;32:D277–D280.
- 24 Watters DJ. Oxidative stress in ataxia telangiectasia. *Redox Rep* 2003;8:23–29.
- 25 Chan EM, Ratanasirintrao S, Park IH et al. Live cell imaging distinguishes bona fide human iPSC cells from partially reprogrammed cells. *Nat Biotechnol* 2009;27:1033–1037.
- 26 Guo Z, Kozlov S, Lavin MF et al. ATM activation by oxidative stress. *Science* 2010;330:517–521.
- 27 Bensimon A, Aebersold R, Shiloh Y. Beyond ATM: The protein kinase landscape of the DNA damage response. *FEBS Lett* 2011;585:1625–1639.
- 28 Xu Y, Ashley T, Brainerd EE et al. Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma. *Genes Dev* 1996;10:2411–2422.
- 29 Houldsworth J, Lavin MF. Effect of ionizing radiation on DNA synthesis in ataxia telangiectasia cells. *Nucleic Acids Res* 1980;8:3709–3720.
- 30 Chen PC, Lavin MF, Kidson C et al. Identification of ataxia telangiectasia heterozygotes, a cancer prone population. *Nature* 1978;274:484–486.
- 31 Taylor AM, Harnden DG, Arlett CF et al. Ataxia telangiectasia: A human mutation with abnormal radiation sensitivity. *Nature* 1975;258:427–429.
- 32 Morgan SE, Kastan MB. p53 and ATM: Cell cycle, cell death, and cancer. *Adv Cancer Res* 1997;71:1–25.
- 33 Pagliarini DJ, Calvo SE, Chang B et al. A mitochondrial protein compendium elucidates complex I disease biology. *Cell* 2008;134:112–123.
- 34 Morizane A, Doi D, Kikuchi T et al. Small-molecule inhibitors of bone morphogenic protein and activin/nodal signals promote highly efficient neural induction from human pluripotent stem cells. *J Neurosci Res* 2011;89:117–126.
- 35 Raya A, Rodriguez-Piza I, Guenechea G et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. *Nature* 2009;460:53–59.
- 36 Kinoshita T, Nagamatsu G, Kosaka T et al. Ataxia-telangiectasia mutated (ATM) deficiency decreases reprogramming efficiency and leads to genomic instability in iPSC cells. *Biochem Biophys Res Commun* 2011;407:321–326.
- 37 Marión RM, Strati K, Li H et al. A p53-mediated DNA damage response limits reprogramming to ensure iPSC cell genomic integrity. *Nature* 2009;460:1149–1153.
- 38 Marion RM, Strati K, Li H et al. Telomeres acquire embryonic stem cell characteristics in induced pluripotent stem cells. *Cell Stem Cell* 2009;4:141–154.
- 39 Pandita TK. ATM function and telomere stability. *Oncogene* 2002;21:611–618.
- 40 Vaziri H. Critical telomere shortening regulated by the ataxia-telangiectasia gene acts as a DNA damage signal leading to activation of p53 protein and limited life-span of human diploid fibroblasts. A review. *Biochemistry (Mosc)* 1997;62:1306–1310.
- 41 Ivanov VN, Zhou H, Partridge MA et al. Inhibition of ataxia telangiectasia mutated kinase activity enhances TRAIL-mediated apoptosis in human melanoma cells. *Cancer Res* 2009;69:3510–3519.
- 42 Fan J, Robert C, Jang YY et al. Human induced pluripotent cells resemble embryonic stem cells demonstrating enhanced levels of DNA repair and efficacy of nonhomologous end-joining. *Mutat Res* 2011;713:8–17.
- 43 Goodarzi AA, Noon AT, Deckbar D et al. ATM signaling facilitates repair of DNA double-strand breaks associated with heterochromatin. *Mol Cell* 2008;31:167–177.
- 44 Momcilovic O, Knobloch L, Fornasoglio J et al. DNA damage responses in human induced pluripotent stem cells and embryonic stem cells. *PLoS One* 2010;5:e13410.
- 45 Valentin-Vega YA, Maclean KH, Tait-Mulder J et al. Mitochondrial dysfunction in ataxia-telangiectasia. *Blood* 2012;119:1490–1500.
- 46 Ambrose M, Goldstine JV, Gatti RA. Intrinsic mitochondrial dysfunction in ATM-deficient lymphoblastoid cells. *Hum Mol Genet* 2007;16:2154–2164.
- 47 Eaton JS, Lin ZP, Sartorelli AC et al. Ataxia-telangiectasia mutated kinase regulates ribonucleotide reductase and mitochondrial homeostasis. *J Clin Invest* 2007;117:2723–2734.
- 48 Fu X, Wan S, Lyu YL et al. Etoposide induces ATM-dependent mitochondrial biogenesis through AMPK activation. *PLoS One* 2008;3:e2009.
- 49 Tang D, Kang R, Livesey KM et al. High-mobility group box 1 is essential for mitochondrial quality control. *Cell Metab* 2011;13:701–711.
- 50 Kang R, Livesey KM, Zeh HJ 3rd et al. Metabolic regulation by HMGB1-mediated autophagy and mitophagy. *Autophagy* 2011;7:1256–1258.
- 51 Heiss EH, Schilder YD, Dirsch VM. Chronic treatment with resveratrol induces redox stress- and ataxia telangiectasia-mutated (ATM)-dependent senescence in p53-positive

cancer cells. *J Biol Chem* 2007;282:26759–26766.

52 Patel AY, McDonald TM, Spears LD et al. Ataxia telangiectasia mutated influences cytochrome c oxidase activity. *Biochem Biophys Res Commun* 2011;405:599–603.

53 Barlow C, Dennery PA, Shigenaga MK et al. Loss of the ataxia-telangiectasia gene product causes oxidative damage in target organs. *Proc Natl Acad Sci USA* 1999;96:9915–9919.

54 Browne SE, Roberts LJ 2nd, Dennery PA et al. Treatment with a catalytic antioxidant

corrects the neurobehavioral defect in ataxia-telangiectasia mice. *Free Radic Biol Med* 2004;36:938–942.

55 Chen P, Peng C, Luff J et al. Oxidative stress is responsible for deficient survival and dendritogenesis in purkinje neurons from ataxia-telangiectasia mutated mutant mice. *J Neurosci* 2003;23:11453–11460.

56 Cosentino C, Grieco D, Costanzo V. ATM activates the pentose phosphate pathway promoting anti-oxidant defence and DNA repair. *EMBO J* 2011;30:546–555.

57 Lim J, Hao T, Shaw C et al. A protein-protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration. *Cell* 2006;125:801–814.

58 Muguruma K, Nishiyama A, Ono Y et al. Ontogeny-recapitulating generation and tissue integration of ES cell-derived Purkinje cells. *Nat Neurosci* 2010;13:1171–1180.

59 Tao O, Shimazaki T, Okada Y et al. Efficient generation of mature cerebellar Purkinje cells from mouse embryonic stem cells. *J Neurosci Res* 2010;88:234–247.



See www.StemCellsTM.com for supporting information available online.